|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
CTG008398186 |
| 003 |
DE-627 |
| 005 |
20230425180614.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
220429s2023 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)CTG008398186
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2022-000035-23-NL
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)VLA2001-307
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a Immune response of VLA2001 Booster vaccine in adults who received mRNA COVID-19 vaccines, have been SARS-CoV-2 naturally infected or had a combination of both
|b OPEN-LABEL PHASE 2/3 CLINICAL STUDY TO INVESTIGATE SAFETY AND IMMUNOGENICITY OF A SINGLE VLA2001 BOOSTER VACCINATION IN ADULT VOLUNTEERS, AFTER RECEIPT OF NATIONALLY ROLLED OUT MRNA COVID-19 VACCINES AND/ OR NATURAL SARS-COV-2 INFECTION. - VLA2001 booster after priming with mRNA COVID-19 vaccine and/or natural SARS-CoV-2 infection
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 05-02-2022, Last updated: 2023-01-13
|
| 650 |
|
4 |
|a Medical Condition: Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. MedDRA version: 23.1Level: PTClassification code 10084458Term: COVID-19 prophylaxisSystem Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 2
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 09. Jan.
|
| 773 |
1 |
8 |
|g year:2023
|g day:09
|g month:01
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2022-000035-23
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2023
|b 09
|c 01
|
Klinische Studie